Related Experiment Videos
Androgen-secreting adrenal tumors
F Sciarra1, C Tosti-Croce, V Toscano
1Istituto di V Clinica Medica Generale, III Endocrinologia, Università degli Studi di Roma La Sapienza.
Minerva Endocrinologica
|March 1, 1995
Summary
Rare virilizing adrenal tumors, adenomas, and adenocarcinomas present distinct hormonal profiles. Differentiating these tumors involves hormonal analysis and imaging, as they often lack typical responses to suppression and stimulation tests.
Area of Science:
- Endocrinology
- Oncology
- Medical Diagnostics
Background:
- Virilizing adrenal tumors, including adenomas and adenocarcinomas, are uncommon endocrine neoplasms.
- Clinical presentations vary significantly based on patient age and tumor type.
- Distinguishing these tumors from other androgen-excess conditions is clinically important.
Purpose of the Study:
- To characterize the hormonal profiles of virilizing adrenal adenomas and adenocarcinomas.
- To compare these profiles with congenital adrenal hyperplasia.
- To discuss diagnostic challenges and potential molecular mechanisms.
Main Methods:
- Retrospective analysis of hormonal status (androstenedione, testosterone, dehydroepiandrosterone, dehydroepiandrosterone sulfate, 17alpha-hydroxyprogesterone, cortisol, estrogen) in patients with adrenal tumors.
- Comparison with patients diagnosed with congenital adrenal hyperplasia.
- Review of imaging findings (CT, NMR) and response to dexamethasone suppression and ACTH stimulation tests.
Main Results:
- Adenomas typically show elevated androstenedione and testosterone.
- Carcinomas are characterized by hypersecretion of dehydroepiandrosterone and its sulfate.
- 17alpha-hydroxyprogesterone and cortisol levels are usually normal or slightly elevated, unlike in congenital adrenal hyperplasia.
Conclusions:
- Distinct hormonal signatures aid in differentiating adrenal adenomas from adenocarcinomas.
- Virilizing adrenal tumors often exhibit resistance to standard hormonal suppression/stimulation tests.
- Potential molecular mechanisms, including G-protein signaling and cytochrome P450 pathways, may underlie androgen overproduction.